Cargando…

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis

BACKGROUND: Disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of rheumatoid arthritis (RA) treatment. However, the full benefits of DMARDs are often not realized because many patients are sub-optimally adherent to their medication. In order to optimize adherence, it is essential th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voshaar, M. J. H., van den Bemt, B. J. F., van de Laar, M. A. F. J., van Dulmen, A. M., Vriezekolk, J. E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756692/ https://www.ncbi.nlm.nih.gov/pubmed/35022034 http://dx.doi.org/10.1186/s12913-021-07459-0

Ejemplares similares

Ranking facilitators and barriers of medication adherence by patients with inflammatory arthritis: a maximum difference scaling exercise
por: Voshaar, M. J. H., et al.
Publicado: (2021)

Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
por: Voshaar, Marieke, et al.
Publicado: (2016)

A Serious Puzzle Game to Enhance Adherence to Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Systematic Development Using Intervention Mapping
por: Pouls, Bart PH, et al.
Publicado: (2022)

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
por: Van De Laar, Celine J, et al.
Publicado: (2020)

Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search
por: Roodenrijs, Nadia M T, et al.
Publicado: (2022)

Electronic Monitoring Feedback for Improving Medication Adherence and Clinical Outcomes in Early Rheumatoid Arthritis: A Randomized Clinical Trial
por: van Heuckelum, Milou, et al.
Publicado: (2021)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

Exploring healthcare professionals’ knowledge, attitudes and experiences of shared decision making in rheumatology
por: Mathijssen, Elke G E, et al.
Publicado: (2020)

Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?
por: Pasma, Annelieke, et al.
Publicado: (2017)

Psychometric properties and cross-language equivalence of the revised Bristol Rheumatoid Arthritis Fatigue and the Rheumatoid Arthritis Impact of Disease scales in rheumatoid arthritis
por: Oude Voshaar, Martijn A. H., et al.
Publicado: (2019)

Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis
por: Zwikker, Hanneke E, et al.
Publicado: (2014)

Gaming for Adherence to Medication using Ehealth in Rheumatoid arthritis (GAMER) study: a randomised controlled trial
por: Pouls, Bart P H, et al.
Publicado: (2022)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions
por: van der Leeuw, Matthijs S., et al.
Publicado: (2022)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis
por: Mathijssen, Elke GE, et al.
Publicado: (2018)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
por: Wientjes, Maike H. M., et al.
Publicado: (2021)

Psychosocial predictors of non-adherence to chronic medication: systematic review of longitudinal studies
por: Zwikker, Hanneke E, et al.
Publicado: (2014)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry
por: van de Laar, Celine J., et al.
Publicado: (2019)

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis
por: Sharma, Chanakya, et al.
Publicado: (2020)

A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement, and selection of attributes and levels
por: Mathijssen, Elke GE, et al.
Publicado: (2018)

Disentangling Rheumatoid Arthritis Patients’ Implicit and Explicit Attitudes toward Methotrexate
por: Linn, Annemiek J., et al.
Publicado: (2016)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs
por: Rigby, William F. C., et al.
Publicado: (2017)

Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
por: Kuijper, T. Martijn, et al.
Publicado: (2017)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
por: van der Togt, Céleste J.T., et al.
Publicado: (2022)

bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
por: Verhoef, Lise M., et al.
Publicado: (2017)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors
por: Gieling, Job, et al.
Publicado: (2022)

Measurement properties of physical function scales validated for use in patients with rheumatoid arthritis: A systematic review of the literature
por: Oude Voshaar, Martijn AH, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fmgh1l0s2g34vm0mr1fqhj30ti